Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026
Journal of Gastroenterology · 2026-06 · 61 (6) · 693-710
DOI: 10.1007/s00535-026-02408-2 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Gastroenterology, online erschienen am 13.05.2026. Verfasst von Norio Akuta und 44 weiteren Autor:innen. Beteiligte Einrichtung: Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Live…. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver-related events and improving long-term outcomes. This guideline summarizes current evidence and provides practical recommendations for the diagnosis, risk stratification, and management of MASLD in clinical practice. These recommendations were developed through systematic evaluation of the literature and expert consensus. Diagnostic approaches, including noninvasive fibrosis assessment tools, imaging, biochemical testing, and indications for referral to gastroenterology/hepatology specialists, were reviewed. Advanced fibrosis is the major determinant of liver-related morbidity and mortality in MASLD. The Fibrosis-4 (FIB-4) index is a widely accessible and reliable first-line noninvasive tool for fibrosis risk stratification. Patients with elevated FIB-4 values or clinical features suggestive of progressive liver injury should undergo secondary assessment with elastography and be referred to a specialist when appropriate. Liver biopsy is not routinely required for the diagnosis of MASLD but remains essential for establishing a definitive diagnosis of at-risk metabolic dysfunction-associated steatohepatitis (MASH), assessing inflammatory activity, resolving discrepancies between noninvasive tests, and differentiating MASLD from other chronic liver diseases. Lifestyle modification remains the foundation of management, with pharmacological therapy considered for patients with a high likelihood of at-risk MASH. MASLD represents a heterogeneous disease spectrum in which advanced fibrosis is the key prognostic factor. These guideline recommendations aim to standardize clinical practice and support evidence-based management of MASLD in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease 2026 (3rd Edition)", The Japanese Society of Gastroenterolog…
- Department of Hepatology, Toranomon Hospital, 2-2-2, Toranomon, Minato-ku, Tokyo, 105-8470, Japan.
- Institute of Gastroenterology, Department of Internal Medicine, Tokyo Women's Medical University, 8-1, Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. kogiso.tomomi@twmu.ac.jp.
- The Japan Society of Hepatology, Kashiwaya 2 Building 5 F, 3-28-10 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
ORCID-Profile: Tomomi Kogiso
Zitieren
APA
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., Hikita, H., Fujii, H., Yamaguchi, K., Yoneda, M., Kon, K., Uchiyama, A., Seko, Y., Sakane, S., Shigefuku, R., Fujiwara, N., …, & Mochida, S. (2026). Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Journal of Gastroenterology, 61(6), 693-710. https://doi.org/10.1007/s00535-026-02408-2
Vancouver
Akuta N, Kogiso T, Ikejima K, Otsuka M, Kawaguchi T, Kawanaka M, et al. Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026. Journal of Gastroenterology. 2026;61(6):693-710. doi:10.1007/s00535-026-02408-2
BibTeX
@article{Akuta2026,
author = {Akuta, Norio and Kogiso, Tomomi and Ikejima, Kenichi and Otsuka, Motoyuki and Kawaguchi, Takumi and Kawanaka, Miwa and Takahashi, Hirokazu and Tamaki, Nobuharu and Nakagawa, Hayato and Hikita, Hayato and Fujii, Hideki and Yamaguchi, Kanji and Yoneda, Masato and Kon, Kazuyoshi and Uchiyama, Akira and Seko, Yuya and Sakane, Sadatsugu and Shigefuku, Ryuta and Fujiwara, Naoto and Iwaki, Michihiro and Kobayashi, Takashi and Adachi, Takuya and Takeuchi, Yasuto and Tsutsumi, Tsubasa and Nakano, Dan and Shibayama, Kaoru and Urata, Noriyo and Miyaaki, Hisamitsu and Kuroda, Hidekatsu and Koseki, Masahiro and Sone, Hirohito and Matsubayashi, Yasuhiro and Kakisaka, Keisuke and Takai, Atsushi and Notsumata, Kazuo and Seike, Masataka and Takei, Yoshiyuki and Takeyama, Yoshifumi and Eguchi, Susumu and Watanabe, Sumio and Isomoto, Hajime and Yotsuyanagi, Hiroshi and Itoi, Takao and Takehara, Tetsuo and Mochida, Satoshi},
title = {Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {6},
pages = {693--710},
doi = {10.1007/s00535-026-02408-2}
}
EUVIMED